Abzyme Therapeutics is a biopharmaceutical company located outside Philadelphia, specializing in modular antibody discovery and conditionally-active antibody engineering. 

Unique to Abzyme is our proprietary antibody discovery/optimization platform based on our self-diversifying yeast display libraries. Using FACS single-cell sorting, we can rapidly undertake multiple rounds of screening to identify candidate antibodies with nanomolar to picomolar affinity. Abzyme’s antibody optimization platform allows for real-time screening based on properties such as epitope diversity, cross-reactivity, pH-dependent activity, expressibility, solubility, developability, and binding profile.

Abzyme develops both agonistic and antagonistic antibodies, conditionally-active antibodies and antibodies with multi-specificities, all at high affinity. Today, the Company has over 60 therapeutic and diagnostic assets in development for infectious diseases, cancer, ophthalmology, inflammation and central nervous system disorders.